The present study aimed to explore whether gamma-aminobutyric acid (GABA) B receptor 2 (GABBR2), which belongs to the G protein-coupled receptor superfamily, functions as a downstream effector of AR and induces resistance to CDDP therapy in bladder cancer. The gene discussed is GABBR2; the disease is urinary bladder carcinoma.